Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus low-dose radiotherapy with concurrent and adjuvant temozolomide for high-risk molecularly selected low-grade glioma
ChiCTR2000029334Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioma (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Overall survival and Health-related quality of life. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2000029334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029334.